Page 28 - pest-POSTEN nr 1-2, 2020

TIME TO RETHINK THE

WAY WE TREAT HIV?

A NEW TREATMENT WITH
DOLUTEGRAVIR AT THE CORE FOR
TREATMENT-NAÏVE PATIENTS

WITH DOLUTEGRAVIR
AT THE CORE 1

FEWER ARVS VS A 3-DRUG REGIMEN:
TDF, TAF AND ABC-FREE 1

Due to the potential risk of neural tube defects,
DOVATO should not be used during the first
trimester unless there is no alternative.
DOVATO is indicated for the treatment of HIV-infected
adults and adolescents above 12 years of age weighing
at least 40 kg, with no known or suspected resistance
to the integrase inhibitor class, or lamivudine.

Dovato er tilgjengelig i nytt anbud.
Se LIS avtaledokument i perioden
01.12.2019 – 30.11.2021 2

References: 1. DOVATO (dolutegravir/lamivudine) Summary of Product Characteristics. July 2019 , section 2.
2. LIS avtaledokument (LIS HIV avtale i perioden 01.12.2019 – 30.11.2021) (https://sykehusinnkjop.no/seksjon/
nyheter/Documents/HIV-seminar%202019/Helseforetakenes%20LIS%20hiv%20anbefalinger%202019_
offentlig%20uten%20priser.pdf Sett 22.11.19).
Trademarks are owned by or licensed to the ViiV Healthcare group of companies.
©2019 ViiV Healthcare group of companies or its licensor. gskpro.no/dovato

16.01.2020 09:27:19
dovato-nov2019-168x238-b.indd 1 16.01.2020 09:27:19
dovato-nov2019-168x238-b.indd 1